Zenas BioPharma grants 37,000 options to director
Zenas BioPharma, Inc. (ZBIO) reported that director Christy J. Oliger received a grant of 37,000 stock options on September 1, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Zenas BioPharma, Inc. (ZBIO) reported that director Christy J. Oliger received a grant of 37,000 stock options on September 1, 2026. The options have an exercise price of $31.98 per share and expire on August 31, 2036. The award vests in equal annual installments over three years beginning September 1, 2027, subject to continued service, and no Rule 10b5-1 trading plan is reported.
Insider Trade Summary
Grant/Award: 37,000 shares
Grant/Award
1 txn
Insider
Oliger Christy J.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 37,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 37,000 contracts (Direct)
Footnotes (1)
- F1. The option vests in equal annual installments over three years beginning on September 1, 2027, the first anniversary of the vesting commencement date, subject to continued service.
Key Figures
Stock options granted: 37,000 options
Exercise price: $31.98 per share
Options held after transaction: 37,000 options
+2 more
5 metrics
Stock options granted
37,000 options
Grant to director on September 1, 2026
Exercise price
$31.98 per share
Exercise price of the stock options granted on September 1, 2026
Options held after transaction
37,000 options
Total stock options directly held by the director following the grant
Option expiration date
August 31, 2036
Expiration of the granted stock options if not exercised earlier
Vesting period
3 years
Options vest in equal annual installments over three years from September 1, 2027
Key Terms
Stock Option, exercise price, vesting commencement date
3 terms
Stock Option financial
"The option vests in equal annual installments over three years"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion or exercise price: 31.9800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting commencement date financial
"beginning on September 1, 2027, the first anniversary of the vesting commencement date"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ZBIO disclose for Christy J. Oliger?
Zenas BioPharma disclosed that director Christy J. Oliger received a grant of 37,000 stock options on September 1, 2026, as an award, with no cash price paid at grant and an exercise price of $31.98 per share.
What is the exercise price and term of the new ZBIO stock options?
The newly granted stock options have an exercise price of $31.98 per share and will expire on August 31, 2036, giving the director a 10-year period from the grant date to exercise the options, subject to vesting and continued service.
How do the 37,000 ZBIO options vest for the director?
The 37,000 stock options vest in equal annual installments over three years, starting on September 1, 2027. Each yearly installment is subject to the director’s continued service with Zenas BioPharma through the relevant vesting date.
How many ZBIO options does the director hold after this grant?
After this award, the director is reported as directly holding 37,000 stock options related to Zenas BioPharma common stock. This reflects the full amount of the new grant, as reported following the transaction on September 1, 2026.
Was the ZBIO option grant made under a Rule 10b5-1 trading plan?
No. The filing indicates that no Rule 10b5-1 trading plan applies to this transaction, so the option grant is reported as a standard equity compensation award rather than part of a pre-arranged trading program.
AI-generated analysis. How Rhea-AI works. Not financial advice.
